Yi-Fan Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yi-Fan Feng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ji Hu
School of Life Science and Technology, ShanghaiTech University, Shanghai, China
2 shared publications - Bingbing Cheng
TRUTH Lab, School of Biomedical Engineering, ShanghaiTech University, Shanghai, China
1 shared publication Fang Cai
School of Life Science and Technology, ShanghaiTech University , Shanghai 201210
1 shared publication- Hengxiang Cui
Shanghai Key Laboratory of Psychotic Disorders, Brain Health Institute, National Center for Mental Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine
1 shared publication Jia-Ji Pan
Translational Research in Ultrasound Theranostics Laboratory, School of Biomedical Engineering, ShanghaiTech University
1 shared publicationKe-Xin Yang
School of Life Science and Technology, ShanghaiTech University , Shanghai 201210
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (35)
Precise antibody delivery to the brain via nanobubble-actuated focused ultrasound alleviates depression
Precise, noninvasive drug delivery to small but important brain regions is challenging and highly desired given the brain’s inherent complexity and heterogeneous nature. Here, we report an approach utilizing focused ultrasound (FUS) combined with nanobubbles to successfully navigate this challenge. Compared to traditional microbubbles, nanobubbles exhibit superior acoustic properties. The nanobubbles, when exposed to FUS, induce a highly localized and reversible opening of the blood–brain barrier (BBB) with significantly enhanced precision (up to fourfolds compared to microbubbles, as measured by the precision loss metric). Repeated multitarget FUS-NB precisely delivers macromolecular human-derived anti-N-methyl-D-aspartate receptors monoclonal antibodies (HuMAbs) into the small brain region within a 2-h half-life window per opening. Fluorescence images confirm HuMAb retention in the brain parenchyma for at least 10 d postadministration. With this approach, we targeted the lateral habenula, a small but effective brain target for antidepressant treatments, and significantly alleviated depression-like symptoms at least 2 wk in a mouse model (tail suspension test/forced swim test: P < 0.01/0.05). Moreover, minimal red blood cell extravasation (0.9‱ affected area) was observed in the treated region after multiple FUS treatments, indicating the safety and tolerability of FUS-nanobubble-mediated BBB opening. The enhanced delivery precision, coupled with a favorable safety profile, positions our approach as a promising strategy for antibody therapy with significant clinical translation potential.
- 27 August 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (35)
Open AccessPrecise antibody delivery to the brain via nanobubble-actuated focused ultrasound alleviates depression
Precise, noninvasive drug delivery to small but important brain regions is challenging and highly desired given the brain’s inherent complexity and heterogeneous nature. Here, we report an approach utilizing focused ultrasound (FUS) combined with nanobubbles to successfully navigate this challenge. Compared to traditional microbubbles, nanobubbles exhibit superior acoustic properties. The nanobubbles, when exposed to FUS, induce a highly localized and reversible opening of the blood–brain barrier (BBB) with significantly enhanced precision (up to fourfolds compared to microbubbles, as measured by the precision loss metric). Repeated multitarget FUS-NB precisely delivers macromolecular human-derived anti-N-methyl-D-aspartate receptors monoclonal antibodies (HuMAbs) into the small brain region within a 2-h half-life window per opening. Fluorescence images confirm HuMAb retention in the brain parenchyma for at least 10 d postadministration. With this approach, we targeted the lateral habenula, a small but effective brain target for antidepressant treatments, and significantly alleviated depression-like symptoms at least 2 wk in a mouse model (tail suspension test/forced swim test: P < 0.01/0.05). Moreover, minimal red blood cell extravasation (0.9‱ affected area) was observed in the treated region after multiple FUS treatments, indicating the safety and tolerability of FUS-nanobubble-mediated BBB opening. The enhanced delivery precision, coupled with a favorable safety profile, positions our approach as a promising strategy for antibody therapy with significant clinical translation potential.
- Open Access
- 12 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (5) , 1652-1664
Parvalbumin neurons mediate neurological phenotypes of anti-NMDAR encephalitis
Patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, often present with severe psychiatric symptoms, yet the neuropathological mechanisms underlying their cognitive deficits remain insufficiently understood. In this study, we constructed an animal model using anti-NMDAR IgG purified from the serum of patients with anti-NMDAR encephalitis, and we used IgG obtained from healthy individuals as a control. Daily administration of anti-NMDAR IgG into the medial prefrontal cortex (mPFC) of mice for 7 days resulted in cognitive impairments resembling clinical symptoms, which spontaneously resolved 30 days after discontinuing the injections. Immunohistochemical staining and electrophysiological testing of parvalbumin neurons in the mPFC treated with anti-NMDAR IgG revealed significant cellular morphological damage, reduced excitability, synaptic dysfunction and a loss of NMDAR antagonist-induced gamma oscillations. Application of optogenetic and pharmacogenetic techniques to activate parvalbumin neurons in the mPFC successfully reversed the cognitive impairments observed in the anti-NMDAR-IgG-treated mice. Single-cell sequencing of anti-NMDAR-IgG-treated parvalbumin neurons identified differentially expressed genes and pathways related to synapses and neuronal development, offering potential targets for therapeutic intervention. Additionally, we showed that these alterations in parvalbumin neurons were not confined to the mPFC, as similar changes were detected in the hippocampus after anti-NMDAR IgG injections. In summary, our findings elucidate distinct alterations in parvalbumin neurons during the pathogenesis of anti-NMDAR encephalitis, providing preclinical rationale for exploring approaches to modulate parvalbumin neuronal function to treat anti-NMDAR encephalitis.
- 12 March 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 148 (5) , 1652-1664
Open AccessParvalbumin neurons mediate neurological phenotypes of anti-NMDAR encephalitis
Patients with anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, often present with severe psychiatric symptoms, yet the neuropathological mechanisms underlying their cognitive deficits remain insufficiently understood. In this study, we constructed an animal model using anti-NMDAR IgG purified from the serum of patients with anti-NMDAR encephalitis, and we used IgG obtained from healthy individuals as a control. Daily administration of anti-NMDAR IgG into the medial prefrontal cortex (mPFC) of mice for 7 days resulted in cognitive impairments resembling clinical symptoms, which spontaneously resolved 30 days after discontinuing the injections. Immunohistochemical staining and electrophysiological testing of parvalbumin neurons in the mPFC treated with anti-NMDAR IgG revealed significant cellular morphological damage, reduced excitability, synaptic dysfunction and a loss of NMDAR antagonist-induced gamma oscillations. Application of optogenetic and pharmacogenetic techniques to activate parvalbumin neurons in the mPFC successfully reversed the cognitive impairments observed in the anti-NMDAR-IgG-treated mice. Single-cell sequencing of anti-NMDAR-IgG-treated parvalbumin neurons identified differentially expressed genes and pathways related to synapses and neuronal development, offering potential targets for therapeutic intervention. Additionally, we showed that these alterations in parvalbumin neurons were not confined to the mPFC, as similar changes were detected in the hippocampus after anti-NMDAR IgG injections. In summary, our findings elucidate distinct alterations in parvalbumin neurons during the pathogenesis of anti-NMDAR encephalitis, providing preclinical rationale for exploring approaches to modulate parvalbumin neuronal function to treat anti-NMDAR encephalitis.